Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 4CMenB and MenACWY-CRM in At-Risk Adults
NCT00560313Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2007
- Primary completion
- Nov 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of recombinant neisseria meningitidis group B nhba fusion protein in meningococcal disease, sponsored by Novartis. Started Jul 2007; status: completed.
02
Drugs
recombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT00560313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00560313.